- cafead Feb 12, 2025 at 11:32: AM
via The company's HIV sales surged 16% during the fourth quarter, setting the scene for its anticipated summer launch of long-acting PREP candidate lenacapivir.
article source
article source
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
- Thread starter cafead
- Start date